Tag: Fgfr inhibitor

In a pivotal clinical trial, Erdafitinib demonstrated a 40% objective response rate in patients with advanced urothelial carcinoma and specific genetic alterations [1.10.3]. Understanding **what is the price of Erdafitinib 4mg** is a critical step for patients considering this targeted therapy.

Erdafitinib is the official generic name for the targeted cancer drug sold under the brand name Balversa. Despite being approved by the FDA in 2019, a generic version is not yet available on the market due to patent protection. This article explores the specifics of erdafitinib, its brand name, and the timeline for potential generic availability.

As the first targeted therapy for bladder cancer with specific genetic mutations, Balversa (erdafitinib) represents a significant advancement in oncology. Understanding how does Balversa work involves delving into its precise mechanism of action as a potent fibroblast growth factor receptor (FGFR) inhibitor.